Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
48,372,275
-
Shares change
-
+14,936,280
-
Total reported value, excl. options
-
$443,043,185
-
Value change
-
+$137,759,207
-
Put/Call ratio
-
33%
-
Number of buys
-
51
-
Number of sells
-
-27
-
Price
-
$9.16
Significant Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q1 2023
111 filings reported holding AVDL - AVADEL PHARMACEUTICALS - COM as of Q1 2023.
AVADEL PHARMACEUTICALS - COM (AVDL) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48,372,275 shares
.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (6,826,787 shares), RTW INVESTMENTS, LP (5,741,939 shares), GENDELL JEFFREY L (5,301,914 shares), Polar Capital Holdings Plc (4,572,490 shares), Vivo Capital, LLC (3,761,438 shares), COWEN AND COMPANY, LLC (3,732,778 shares), WEALTH EFFECTS LLC (2,498,838 shares), Woodline Partners LP (1,879,343 shares), BRANDES INVESTMENT PARTNERS, LP (1,444,635 shares), and Samsara BioCapital, LLC (1,409,409 shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.